Partners Group’s Post

Gene&Cell Therapy >> AbbVie pours $223M into building out its biologics capacity in Singapore: AbbVie is not only building out its pipeline, but also its manufacturing footprint. The Chicago-based pharma is spending $223 million to extend its only manufacturing site in Asia and boost its biologics production. The facility in Singapore, which can already produce biologics and small molecules, is envisioned to add at least 100 jobs to a total of around 500 workers once it’s fully operational. The extension will boost its biologics drug substance capabilities by 24,000 liters. The addition is not only designed to make AbbVie’s current marketed products, but also its immunology and oncology assets in clinical trials. The project is scheduled to start later in 2024, with 2026 earmarked as the start of operations. With its blockbuster Humira starting to face biosimilar competitors, AbbVie made a couple of recent high-profile acquisitions: ADC biotech ImmunoGen in a deal worth $10.1 billion and CNS company Cerevel for $8.7 billion. A few weeks ago, AbbVie secured a licensing partnership with CAR-T focused Umoja Biopharma that could be worth up to $1.44 billion. Ab­b­Vie bets that near­ly $20B in deals can bring it in­to the post-Hu­mi­ra fu­ture The Singaporean facility at Tuas Biomedical Park has been the center of at least $740 million in investment from AbbVie, from when it was acquired to subsequent buildouts in the past decade, a Friday press release states. The Big Pharma has more than 30 logistics, manufacturing and operations facilities globally, with 14,000 staffers. #lucidquest #genetherapy #celltherapy

🗞 Richardson Round Up 🗞 Happy Weekend Eve everyone! This week brought some exciting new Partnerships and Acquisitions. Here are some highlights: 💊 Samsung Biologics and LegoChem Biosciences have signed an ADC partnership agreement. Samsung Biologics will provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences' ADC program designed to treat solid tumors. 📢 Jazz Pharmaceuticals to acquire Redx Pharma’s KRAS Inhibitor Program to advance candidates through IND-enabling studies, and Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities. 🤝 MSD has entered into a multi-year agreement with the Vector Institute, allowing Merck Canada to gain access to Vector's research capabilities and expertise in AI and engage with its ecosystem to drive innovation in healthcare. ✅ mAbxience and BIOSIDUS Enter CDMO Agreement, mAbxience will be responsible for the manufacturing of the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme. Keep an eye out for next week's Richardson Round Up. Have a great weekend! #cdmo #contractmanufacturing #pharmaceutical #pharma #bioscience

We are excited to announce our participation and sponsorship at the upcoming "2nd Annual Australian Biologics Festival 2024" conference on February 20th to 21st in Melbourne, Australia. 👥 Meet Karen Montgomery-Douglas and May Mitropoulos, key representatives from Akesa, as we look into the dynamic landscape of Australia's biotechnology sector. The conference will be a premier platform to explore the latest in Biologics, Biosimilars, Vaccines, CGT, and evolving therapeutics, covering ideation to commercialisation and beyond. Australia's biotechnology sector, known for its world-class facilities, researchers, and regulatory standards, holds immense potential for innovation and manufacturing in biologics. Akesa recognises the crucial role of partnerships and collaborations in the commercial translation of research and the expansion of sovereign manufacturing, contributing significantly to the sector's growth in the country. 🌟 Event Highlights: - Date: February 20-21, 2024 - Venue: Melbourne, Australia - Visit Akesa at Booth: 10 - Focus Areas: Biologics Innovation, Clinical Trials, Manufacturing The Australia Biologics Festival 2024 is essential for gathering industry innovators, pioneers, and leaders. With featured tracks on Investment in Australia and Promoting Clinical Trials, the event provides an ideal environment to connect with the entire biopharma industry under one roof. 🔗 Join us at Booth 10 to learn more about how Akesa assists its current clients in ensuring their success as industry leaders. #Akesa #Biopharma #ClinicalTrials #BiologicsInnovation #AustraliaBiologicsFestival2024 #Partnerships #Innovation #Manufacturing #BioSectorGrowth

AI is improving speed and reducing costs at every stage of the drug discovery and development process 💊 Rachel Brazil's article for Pharmaceutical Journal Publications explores how AI is accelerating drug discovery, enhancing precision oncology, and cutting costs. From identifying novel targets to streamlining clinical trials, AI is transforming the pharmaceutical industry. Read more about how companies like Recursion, Lantern Pharma Inc. (Nasdaq: LTRN), and BenevolentAI are leading this journey at https://lnkd.in/gBSNG_at #AI #DrugDiscovery #Pharma #Innovation #Pharmaceuticals #AIforDrugDiscovery #AIforHealthcare

2024 has started with a bang in the bio/pharma contract development & manufacturing space, with a flurry of acquisitions, partnerships and investments in new capabilities announced.  To help keep up, PharmaSource is now tracking all the latest announcements in our CDMO News Hub: BREAKING NEWS: Catalent Pharma Solutions goes private: Novo Holdings Acquires Catalent for $16.5B and Sells 3 Sites to Novo Nordisk Lonza Joins Forces with Oxford Nanopore Technologies to Accelerate mRNA Analytics SUANFARMA CDMO Unifies Manufacturing Plants Under Strategic Rebrand Olon Invests in High Potency API Suite in United States Alcami Corporation Expands West Coast Presence with Acquisition of Pacific Pharmaceutical Services Societal™ CDMO and Benuvia Operations, LLC. Announce Partnership 3P Biopharmaceuticals + Biovian combine to form 3PBIOVIAN Sai Life Sciences Ltd Upscales DMPK Capabilities Agilent Technologies and Incyte: Collaborating for CDx Advancements in Oncology AbbVie Boosts Biologics Capabilities with $223M Investment in Singapore Kindeva Drug Delivery acquires Summit Biosciences Inc. AustinPx + Microsize (Micronization, Particle Size Engineering, Pharmaceutical Development): A Partnership to Accelerate KinetiSol Technology EUROAPI Combines CRO-CDMO Capabilities with SpiroChem Partnership EXO Biologics Launches ExoXpert: A New CDMO Specialising in Exosomes Read all the latest in the PharmaSource #CDMO news hub: https://lnkd.in/e4UEq_-r

3-Signs that investments are returning to the Life Sciences industry.... Recent acquisitions of small drugmakers by major pharmaceutical companies have provided hope for biotechnology venture capitalists following two years of declining investment. This week, there were several drugmaker purchases: 1. GSK bought venture-backed Aiolos Bio for up to $1.4bn to secure an asthma drug. 2. Novartis purchased venture-funded Calypso Biotech, which has a treatment for celiac disease and a clinical trial for an immune disorder, for up to $425m. 3. Publicly traded biotechs Harpoon Therapeutics and Ambrx Biopharma also accepted buyout offers this week. Venture capitalists are optimistic for 2024 due to M&A activity, innovation in the industry, and the prospect of interest rate cuts and an improved IPO market.

Soft Tissue Sarcoma Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Philogen, Epizyme, CytRx, Incyte, Karyopharm, AstraZeneca #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

French biotech, cash position as of Dec 31, 2023: There was a slight improvement in total cash compared to mid-June, but we still had a high number of companies with <EUR 20m and having no financial visibility beyond the end of 2024 (Nicox, POXEL, GenSight Biologics). It should be noted that some biotech were able to significantly strengthen their cash position since January 1, 2024. Valneva sold its PRV for EUR 95m, Sensorion raised EUR 65.5m, OSE Immunotherapeutics received the $48m upfront payment from AbbVie, Nanobiotix received $20m from J&J, Innate Pharma received EUR 19m from Sanofi (2 payments of 15 + 4). Medincell should receive an upfront payment of $ 35m from AbbVie, and to finish with notorious events, GENFIT received EUR 13.3m milestone payment from Ipsen triggered by the acceptance of the NDA filing by the FDA and MAA by EMA for accelerated approval of elafibranor in PBC. Genfit expects to receive additional milestone payments of approximately EUR 76m in 2024.

🌍 Major Developments in European Pharma for 2024 – 🚀 As we look forward to 2024, the European pharmaceutical landscape is buzzing with activity, featuring several significant projects: 1. **Novartis Investments**: A $300 million boost across Switzerland, Slovenia, and Austria to enhance biologics development. Basel, Switzerland, will host a new biologics hub. 2. **Sandoz's New Slovenia Plant**: Part of Novartis, Sandoz is setting up a $400 million biologics production facility in Lendava, Slovenia. 3. **Merck's Expansion in France**: More than €130 million is being invested in expanding Merck’s Molsheim facility for single-use assemblies. 4. **Pfizer's European Expansion**: Over $2.5 billion is being allocated to expand Pfizer's manufacturing sites in Belgium and Ireland. 5. **Pharma Europe 2024 in Switzerland**: The 34th Annual European Pharma Congress promises exciting insights in Zurich. 6. **Lonza's Strategic Moves**: - In Switzerland, Lonza is investing nearly $1 billion in capacity upgrades, including a large-scale mammalian drug substance factory in Visp, which is expected to be operational by 2024, creating over 300 new j [[❞]](https://lnkd.in/exT5dhGS) [[❞]](https://lnkd.in/er5zEbvi) [[❞]](https://lnkd.in/eqai4vBQ. - Additional investments in Switzerland include a new aseptic flexible filling line in Stein for clinical supply and expanded drug product services in Basel and Visp, expected to create over 70 new positions and be operational in 2023 and 2 [[❞]](https://lnkd.in/ewczyXRf) [[❞]](https://lnkd.in/eNvDNuAM. These initiatives not only represent growth for the companies involved but also indicate a robust and innovative trend in the European pharma sector. Stay tuned for more updates as these projects progress! #PharmaIndustry #Healthcare #Biotech #EuropeanPharma #2024Outlook #Lonza #Innovation

📢 New publication from the European Lead Factory! The paper titled "The European Lead Factory: results from a decade of collaborative, public–private, drug discovery programs" reviews the outcomes of the European Lead Factory (ELF) and discusses its unique compound-sharing model, its extensive library, and the screening of these compounds against various targets and phenotypic assays. The ELF facilitated the identification of compounds leading to patents and spin-off companies. The paper highlights the significant impact of this model in drug discovery, emphasizing its potential for future pharmaceutical research and development. Key Highlights: - Creation of a unique compound library through an innovative sharing model - Extensive screening of compounds against diverse targets and assays - Significant outcomes: patents, publications, spin-off companies, and clinical trials The ELF model demonstrates the power of collaborative efforts to advance pharmaceutical research. It's a testament to how shared resources and expertise can lead to remarkable achievements in the discovery of new medicines. Read the full paper for more insights in Drug Discovery Today 👇 #DrugDiscovery #Innovation #Collaboration #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 Joint Undertaking (Innovative Health Initiative (IHI)). Herman van Vlijmen, Andrew D. Pannifer, Phil Cochrane, Daniel Basting, Volkhart Li (PhD), Ola Engkvist, Jean-Yves Ortholand, Markus Wagener, James Duffy, Dirk Finsinger, Jeremy Davis, Steven van Helden, Jon de Vlieger, Bayer, Grünenthal Group, Servier, The Janssen Pharmaceutical Companies of Johnson & Johnson, AstraZeneca, Merck Group, Sanofi, UCB, Lygature, BioAscent, EDELRIS, Symeres, Pivot Park Screening Centre, Sygnature Discovery, Taros Chemicals, National Phenotypic Screening Centre, University of Dundee, University of Oxford, Medicines for Malaria Venture,